Cancer Chemotherapy and Pharmacology

Volume 14 1985

Edited by

S.K. CARTER and T. McELWAIN

Editorial Board

M. Acton Menlo Park
P. Alberto Geneva
R. H. Blum New York
M. Boiron Paris
H. Calvert Sutton
R. L. Comis Syracuse
T. Connors Carshalton
R. C. Coombes Sutton
S. Eckhardt Budapest
B. W. Fox Manchester
R. M. Fox Sydney
S. Garattini Milano
M. Ghione Milano
H. Hansen Copenhagen
K. Karrer Vienne
D. L. Kisner Bethesda
J. Laszlo Durham
R. B. Livingston Seattle
J. S. Macdonald Bethesda
J. G. McVie Amsterdam
F. M. Muggia New York
M. Ogawa Tokyo
P. Martin Marseille
S. Pavlovsky Buenos Aires
P. Potier Gif-sur-Yvette
P. Reizenstein Stockholm
E. Robinson Haifa
M. Rozencweig Brussells
C. G. Schmidt Essen
H. J. Seen St. Gallen
J. Smyth Edinburgh
A. Trouet Brussells
S. Tsukagoshi Tokyo
U. Umezawa Tokyo
L. M. van Putten Rijswijk
F. A. Valeriote Detroit
P. Wilkinson Manchester
G. Wu Huan-Hsin Peking

Springer International

Cancer Chemotherapy and Pharmacology

This journal was founded in 1978. Editors: S. K. Carter, T. McElwain. Published by Springer International.

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher (society); and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or in-house use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page, or a minimum of US $ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0302-8933, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Other regulations: Authors publishing in this journal can, under certain conditions, benefit from library and photocopy fees collected by VG WORT. Authors resident in the Federal Republic of Germany or in West Berlin can apply to Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printed in Germany by Ernst Kieser GmbH Graphischer Betrieb, D-8902 Neusäß

© by Springer-Verlag Berlin Heidelberg 1985

Contents of volume 14

Acton EM, see Streeter DG, et al. 160
Adam N, see Owens SE, et al. 253
Aherne GW, see Pearson ADJ, et al. 211
Ahmed T, see Scher HI, et al. 81
Aisner J, see Jones JM, et al. 172
Alberts DS, see Peng YM, et al. 15
Alison DL, Newell DR, Sessa C, Harland SJ, Hart LI, Harrap KR, Calvert AH: The clinical pharmacokinets of the novel antifolate N^{10}-propargyl-5,8-dideazafolic acid (CB 3717) 265
Ambersley J, see Sarna G, et al. 12
Arbit E, see Panasci LC, et al. 156
Arlin ZA, see Mittelman A, et al. 79
Assandri A, see Galliani G, et al. 74
Atkins JN, see Jackson DV, et al. 26

Bachur NR, see Dodion P, et al. 42
Baer JC, see Owens SE, et al. 253
Bandyopadhyay SK, see Ray, PK, et al. 59
Barneveld van PWC, Veenstra G, Sleijfer DT, van der Mark TW, Mulder NH, Schraffordt Koops H, Sluiter HJ, Peset R: Changes in pulmonary function during and after bleomycin treatment in patients with testicular carcinoma 168
Barone D, see Galliani G, et al. 74
Baume D, see Mascret B, et al. 216
Becherer C, see Steine B, et al. 279
Beghelli P, see Camaggi CM, et al. 232
Belch AR, Henderson JF, Brox LW: Treatment of multiple myeloma with deoxycoformycin 49
Benz C, see Hait WN, et al. 202
Besati A, see Tofanetti O, et al. 188
Bleehen NM, see Lee FYF et al. 125
Bolis G, see Sessa C, et al. 222
Bosanquet AG: Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents 83
Boyd MR, see Kramer RA, et al. 150
Brem S, see Panasci LC, et al. 156
Brenner DE, Galloway S, Cooper J, Noone R, Hande KR: Improved high-performance liquid chromatography assay of doxorubicin: Detection of circulating aglycones in human plasma and comparison with thin-layer chromatography 139
Brox LW, see Belch AR, et al. 49
Budman D, see Scher HI et al. 81
Busch FW, see Steinke B, et al. 279

Cadman EC, see Hait WN, et al. 202
Callahan RD, see Jackson DV, et al. 26
Calman K, see Milsted R, et al. 272
Calvert AH, see Alison DL, et al. 265
Camaggi CM, Strocchi E, Canova N, Costanti B, Pannuti F: Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses 229
Camaggi CM, Strocchi E, Costanti B, Beghelli P, Ferrari P, Pannuti F: Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer 232
Campbell AN, see Pearson ADJ 211
Campbell-Ferguson J, see Millsted R, et al. 272
Canchanapan P, see Ray RK, et al. 59
Canova N, see Camaggi CM, et al. 229
Carcassonne Y, see Mascret B, et al. 216
Caterson ID, see Hedley DW, et al. 112
Cavalletti E, see Tofanetti O, et al. 188
Chan KK, Luesley DM, et al. 250
Chang BK, Gregory JA: Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer 132
Chauvenet AR, see Jackson Jr. DV, et al. 26
Chevalier L, see Panasci LC, et al. 156
Chou TC, see Takemura Y, et al. 206
Christie M, Hedley DW, et al. 112
Cohen A, Ullman B: Analysis of the drug synergism between thymidine and arabinosyl cytosine using mouse S49 T lymphoma mutants 70
Collins JM: Pharmacokinetics of 5-fluorouracil infusions in the rat: Comparison with man and other species 108
Collins JM, see Borden, BJ, et al. 38
Colombo N, see Sessa C, et al. 222
Cooper J, see Brenner DE, et al. 139
Corden BJ, Fine RL, Ozols RF, Collins JM: Clinical pharmacology of high-dose cisplatin 38
Costanti B, see Camaggi CM, et al. 229
Costanti B, see Camaggi CM, et al. 232
Craft AW, see Pearson ADJ, et al. 211
Crowther D, see Owens, SE, et al. 253

Darnowski JW, Sawyer RC, Stolfi RL, Martin DS, Lau-Cam CA: Decreased host toxicity in vivo during chronic treatment with 5-fluorouracil 63
Daugherty JP, Khurana A: Amelioration of doxorubicn-induced skin necrosis in mice by butylated hydroxytoluene 243
Davis TP, see Peng YM, et al. 15
Davy M, Paus E, Lehne G: A pharmacokinetic evaluation of IM administration of belomycin oil suspension 274
Dennis LY, see Hill BT, et al. 194
D'Incalci M, see Sessa C, et al. 222
Dodion P, Rozenczweig M, Nicaise C, Watthieu M, Tamburini JM, Riggs Jr CE, Bachur NR: Human pharmacokinetics of marcellomycin 42
Dohadwala M, see Ray PK, et al. 59
Dohadwala M, Ray PK: In vivo protection by protein A of hepatic microsomal mixed function oxygenase system of cyclophosphamide-treated rats 135
Donker AJM, see Offermann JJG, et al. 262
Dufour M, see Panasci LC, et al. 156

Eastham EJ, see Pearson ADJ, et al. 211
Egorin MJ, see Jones JM, et al. 172
Emi N, see Ohno R, et al. 34
Evans BD, see Smith IE, et al. 120

Feindel W, see Panasci LC, et al. 156
Ferrari P, see Camaggi CM, et al. 232
Figlin R, see Sarna G, et al. 12
Fine RL, see Corden BJ, et al. 38
Florence AT, Azmin MN, et al. 238
Ford HT, see Smith IE, et al. 120
Fossa SD, see Sommer HH, et al. 277
Fox BW, see Owens, SE, et al. 253
Friedland ML, see Mittelman A, et al. 79
Fujiwara K, Sohda M, et al. 53

Galliani G, Assandri A, Barone D, Grandi M, Mistrello G, Lancini GC: Contragestational profile of the tumor-inhibiting agent, L-alanosine, in the rat and the hamster 74
Galloway S, see Brenner DE, et al. 139
Gastaut JA, see Mascret B, et al. 216
Ghos BC, see Metzger UF, et al. 1
Giles Jr, RC, see Harrison SD, et al. 146
Gless JG, see Smith IE, et al. 120
Grais L, see Hait WN, et al. 202
Grandi M, see Galliani G, et al. 74
Gregory JA, see Chang BK, et al. 132
Greve de J, see Schaller D, et al. 235

Groopman J, see Sarna G, et al. 12
Groth S, see Sørensen PG, et al. 247

Habeshaw T, see Milsted R, et al. 272
Hait WN, Grais L, Benz C, Cadman EC: Inhibition of growth of leukemic cells by inhibitors of calmodulin: Phenothiazines and melittin 202
Hande KR, see Brenner DE, et al. 139
Hara K, see Sohda M, et al. 53
Harland SJ, see Smith IE, et al. 120
Harland SJ, see Alison DL, et al. 265
Harrap KR, see Alison DL, et al. 265
Harrison R, see Owens SE, et al. 253
Harrison SD Jr, Mann DM, Giles, Jr RC: Effect of nitrosoureas on calmodulin activity in vitro and in mouse intestine in vivo 146
Hart LI, see Alison DL, et al. 265
Hedley DW, Christie M, Weatherby RP, Caterson ID: Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer 112
Henderson JF, see Belch AR, et al. 49
Hill BT, Dennis LY, Li X-T, Whelan RDH: Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro 194
Holland JF, see Takemura Y, et al. 206
Horchowski N, see Mascret B, et al. 216
Hoshi A, see Matsushima Y, et al. 104

Iida H, see Tsuruo T, et al. 30
Ip M, see Lam WK, et al. 282
Isabel G, see Panasci LC, et al. 156

Jackson DV Jr, Chauvenet AR, Callahan RD, Atkins JN, Trahey TF, Spurr ChL: Phase II trial of vincristine infusion in akute leukemia 26
Jones JM, Olman EA, Egorin MJ, Aisner J: A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide 172
Judson IR, Wiltshaw E: Cis-dichlorodiammineplatinum (Cis-platinum) and etoposide (VP-16) in malignant lymphoma – an effective salvage regimen 258
Jurlina JL, Varcoe AR, Paxton JW: Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia 21

Kanzawa F, see Matsushima Y, et al. 104
Kataoka T, see Yamaoka T, et al. 184
Kawabata H, see Tsuruo T, et al. 30
Kawashima K, see Ohno R, et al. 34
Kaye S, Merry S: Tumor cell resistance to anthracyclines – A review 96
Kaye S, see Milsted R, et al. 272
Khurana A, see Daugherty JP, et al. 243
Kisner DL, see Metzger UF, et al. 1
Kitagawa T, see Sohda M, et al. 53
Klein MA, see Weiss RB, et al. 9
Kobayashi M, see Ohno R, et al. 34
Kodera Y, see Ohno R, et al. 34
Koops HS, see Offermann, JJG, et al. 262
Kramer RA, McMenamin MG, Boyd MR: Differential distribution and covalent binding of two labeled forms of methyl-CCNU in the Fischer 344 rat 150

Lam WK, So SY, Ip M, Yu DYC: Cyclic combination chemotherapy in advanced adenocarcinoma of the lung: Comparison of two FAM schedules 282
Lancini GC, see Galliani G 74
Lau-Cam CA, see Darnowski JW, et al. 63
Lazarus P, see Panasci LC, et al. 156
Lee FYF, Workman P, Roberts JT, Bleehen NM: Clinical pharmacokinetics of oral CCNU (Lomustine) 125
Lehne G, see Davy M et al. 274
Lejeune C, see Mascret B, et al. 216
Li X-T, see Hill BT, et al. 194
Lien HH, see Sommer HH, et al. 277
Lihou MG, Smith PJ: Adriamycin and cytosine arabinoside contribute equally to prediction of response in acute myelocytic leukemia with improved confidence level 116
Littleton P, see Pearson ADJ, et al. 211
Lucas SB, see Stewart AL, et al. 165
Luesley DM, Terry PB, Chan KK: High-dose intravenous metoclopramide and intermittent intramuscular prochlorperazine and diazepam in the management of emesis induced by *cis*-dichlorodiammineplatinum 250

Macbeth F, see Milsted R, et al. 272
Makishima F, see Tsuruo T, et al. 30
Mangioni C, see Sessa C, et al. 222
Mann DM, see Harrison SD, et al. 146
Maraninichi D, see Mascret B, et al. 216
Margison JM, see Stewart AL, et al. 165
Mark van der TW, see van Barneveld PWC, et al. 168
Martin DS, see Darnowski JW, et al. 63
Mascret B, Maraninchi D, Gastaut JA, Baume D, Sebahoun G, Lejeune C, Novakovitch G, Sainty D, Horchowski N, Tubiana N, Carcassonne Y: Phase I–II study of high-dose melphalan and autologous marrow transplantation in adult patients with poor-risk non-Hodgkin's lymphomas 216
Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y, Saijo N: Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay 104
McAuliffe CA, see Owens SE, et al. 253
McLaughlin D, see Ray PK, et al. 59
McMenamin MG, see Kramer RA, et al. 150
McQuillan A, see Panasci LC, et al. 156
Meijer S, see Offermann JJG, et al. 262
Mermillod B, see Sessa C, et al. 222
Merry S, see Kaye S, et al. 96
Metzger UF, Ghosh BC, Kisner DL: Adjuvant treatment of colorectal cancer. Current status and concepts 1
Millsted R, Habeshaw T, Kaye S, Sangster G, Macbeth F, Campbell-Ferguson J, Smith D, Calman K: A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer 272
Minami S, see Ohno R, et al. 34
Mistrello G, see Galliani G, et al. 74
Mitsuyasu R, see Sarna G, et al. 12
Mittelman A, Rieber E, Friedland ML, Arlin ZA: Induction of remission in acute promyelocytic leukemia with mitoxantrone 79
Morishima Y, see Ohno R, et al. 34
Morishita Y, see Ohno R, et al. 34
Mulder NH, see van Barneveld PWC, et al. 168
Mulder NH, see Offermann JJG, et al. 262
Murase T, see Ohno R, et al. 34

Nagura E, see Ohno R, et al. 34
Nakamura N, see Sohda M, et al. 53
Newell DR, see Alison DL, et al. 265
Nicaise C, see Dodion P, et al. 42
Nissen MH, see Sørensen PG, et al. 247
Nomori H, see Matsushima Y, et al. 104
Noone R, see Brenner DE, et al. 139
Noor Azmin M, Stuart JFB, Florence AT: The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80 238
Novakovitch G, see Mascret B, et al. 216

Offermann JJG, Sleijfer DT, Mulder NH, Meijer S, Koops HS, Donker AJM: The effect of captopril on renal function in patients during the first *cis*-diamminedichloroplatinum II infusion 262
Ogura M, see Ohno R, et al. 34

Ohno R, Kodera Y, Ogura M, Murase T, Emi N, Okumura M, Morishita Y, Nagura E, Minami S, Morishima Y, Kawashima K, Yokomaku S, Kobayashi M, Takeyama H: Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon 34
Ohnuma T, see Takemura Y, et al. 206
Okano T, see Takemura Y, et al. 206
Okumura M, see Ohno R, et al. 34
Olman EA, see Jones JM, et al. 172
Ostendorf P, see Steinke B, et al. 279
Owens SE, Thatcher N, Sharma H, Adam N, Harrison R, Smith A, Zaki A, Baer JC, McAuliffe CA, Crowther D, Fox BW: In vivo distribution studies of radioactively labelled platinum complexes; *cis*-dichlorodiammine platinum (II), *cis*-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), *cis*dichloro-bis-cyclopropylamine platinum(II), and *cis*-diammine 1,1-cyclobutanedicarboxylate platinum (II) in patients with malignant disease, using a gamma camera 253
Ozols RF, see Corden BJ, et al. 38

Panasci LC, Dufour M, Chevalier L, Isabel G, Lazarus P, McQuillan A, Arbit E, Brem S, Feindel W: Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners on amino acid amides with increased in vitro activity against human glioma compared with BNCU 156
Pannuti F, see Camaggi CM, et al. 229
Pannuti F, see Camaggi CM, et al. 232
Paus E, see Davy M, et al. 274
Paxton JW, see Jurlina JL, et al. 21
Pearson ADJ, Craft AW, Eastham EJ, Aherne GW, Littleton P, Pearson GL, Campbell AN: Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia 211
Pearson GL, see Pearson ADJ, et al. 211
Peng YM, Alberts DS, Davis TP: In vivo and in vitro metabolism of the new anticancer drug bisantrene 15
Peset R, see van Barneveld PWC, et al. 168
Peters JH, see Streeter DG, et al. 160
Pezzoni G, see Tofanetti O, et al. 188
Powis G: Anticancer drug pharmacodynamics 177
Pratesi G, see Tofanetti O, et al. 188

Ray PK, Dohadwala M, Bandyopadhyay SK, Canchanapan P, McLaughlin D: Rescue of rats from large dose cyclophosphamide toxicity using protein A 59
Ray PK, see Dohadwala M 135
Rieber E, see Mittelman A, et al. 79
Riggs Jr CE, see Dodion P, et al. 42
Roberts JT, see Lee FYF, et al. 125
Robinson BA, see Smith IE, et al. 120
Rørth M, see Sørensen PG, et al. 247
Rozencweig M, see Dodion P, et al. 42

Saijo N, see Matsushima Y, et al. 104
Saikusa H, see Sohda M, et al. 53
Sainty D, see Mascret B, et al. 216
Sakurai Y, see Tamaoka T, et al. 184
Sakurai Y, see Tsuruo T, et al. 30
Sangster G, see Milsted R, et al. 272
Sarna G, Mitsuyasu R, Figlin R, Ambersley J, Groopman J: Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum 12
Sasaki Y, see Matsushima Y, et al. 104
Sawyer RC, see Darnowski JW, et al. 63
Schallier D, Van Belle S, Greve de J, Willekens A: Methylprednisolone as an antiemetic drug. A randomised double blind study 235
Scher HI, Yagoda A, Ahmed T, Budman D, Sordillo P, Watson RC: Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma 81
Schrafford Koops H, see van Barneveld PWC, et al. 168
Sebahoun G, see Mascret B, et al. 216
Sessa C, Bolis G, Colombo N, D'Incalci M, Mermillod B, Valente I, Mangioni C: Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus *cis*-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trial 222
Sessa C, see Alison DL, et al. 265
Sharma H, see Owens SE, et al. 253
Shimizu E, see Matsushima Y, et al. 104
Sleijfer DT, see Offermann JJG, et al. 262
Sleifjer DT, see van Barneveld PWC, et al. 168
Sluiter HJ, van Barneveld PWC, et al. 168
Smith A, see Owens SE, et al. 253
Smith D, see Milsted R, et al. 272
Smith IE, Evans BD, Harland SJ, Robinson BA, Yarnold JR, Glees JG, Ford HT: High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma 120
Smith PJ, see Lihou MG, et al. 116
So SY, see Lam WK, et al. 282
Sohda M, Fijiwara K, Saikusa H, Kitagawa T, Nakamura N, Hara K, Tone H: Sensitive enzyme immunoassay for the quantification of aclacinomycin A using β-D-galactosidase as a label 53
Sommer HH, Fossa SD, Lien HH: Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine 277
Sordillo P, see Scher HI, et al. 81
Sørensen PG, Nissen MH, Groth S, Rørth, M: Beta-2-microglobulin excretion: An indicator of long term nephrotoxicity during *cis*platinum treatment? 247
Spurr ChL, see Jackson DV, et al. 26
Steinke B, Busch FW, Becherer C, Ostendorf P, Waller HD: Melphalan-resistant multiple myeloma: Results of treatment according to the M-2 protocol 279
Stewart AL, Margison JM, Wilkinson PM, Lucas SB: The pharmacokinetics of 7-hydroxy-methotrexate following medium-dose methotrexate therapy 165
Stolfi RL, see Darnowski JW, et al. 63
Streeter DG, Taylor DL, Acton EM, Peters JH: Comparative cytotoxicities of various morpholinyl anthracyclines 160
Strocchi E, see Camaggi CM, et al. 232
Strocchi E, Camaggi CM, et al. 229
Stuart JFB, see Noor Azim M, et al. 238

Takada H, see Yamaoka T, et al. 184
Takemura Y, Ohnuma T, Chou T-C, Okano T, Holland JF: Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells 206
Takeyama H, see Ohno R, et al. 34
Tamburini JM, see Diodon P, et al. 42
Taylor DL, see Streeter DG, et al. 160
Terry PB, see Luesley DM, et al. 250
Thatcher N, see Owens SE, et al. 253
Tofanetti O, Cavalletti E, Besati A, Pratesi G, Pezzoni G, Zunino F: Prevention of cyclophosphamide -induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent 188
Tone H, see Sohda M, et al. 53
Trahey TF, see Jackson DV, et al. 26
Tsukagoshi S, see Tsuruo T, et al. 30
Tsuruo T, Iida H, Makishima F, Yamari T, Kawabata H, Tsukagoshi S, Sakurai Y: Inhibition of spontaneous and experimental tumor metastasis by the calcium antagonist verapamil 30
Tubiana N, see Mascret B, et al. 216

Ullman B, see Cohen A 70

Valente I, see Sessa C, et al. 222
van Belle S, see Schaller D, et al. 235
Varcoe AR, see Jurlina JL, et al. 21
Veenstra G, see van Barneveld PWC, et al. 168

Waller HD, see Steinke B, et al. 279
Watson RC, see Scher HI, et al. 81
Watthieu M, see Dodion P, et al. 42
Weatherby RP, see Hedley DW, et al. 112
Weiss RB, Klein MA: Non-Hodgkin's lymphoma after successful therapy of small cell lung carcinoma 9
Whelan RDH, see Hill BT, et al. 194
Wilkinson PM, see Stewart AL, et al. 165
Willekens A, see Schaller D, et al. 235
Wiltshaw E, see Judson IR 258
Workman P, see Lee FYF, et al. 125

Yagoda A, see Scher HI, et al. 81
Yamaoka T, Takada H, Yanagi Y, Kataoka T, Sakurai Y: The anti-tumor effects of human lymphoblastoid interferon on human renal cell carcinoma in athymic nude mice 184
Yamari T, see Tsuruo T, et al. 30
Yanagi Y, see Yamaoka T, et al. 184
Yarnold JR, see Smith IE, et al. 120
Yokomaku S, see Ohno R, et al. 34
Yu DYC, see Lam WK, et al. 282

Zaki A, see Owens SE, et al. 253
Zunino F, see Tofanetti O, et al. 188

Subject index — Volume 14

Aclacinomycin A 53
Acute myeloid leukemia 116
Adjuvant therapy 1
Adriamycin 194, 222, 243
Alkylating agent 188
Amino acid 145
Aminoglutethimide 272
Amsacrine 21
Anthracycline 96, 194
Anti-emetic therapy 235
Anticancer drugs 104
Arabinosyl cytosine 70
Athymic nude mice 184

BCNU 156
Beta-2-microglobulin and cis-platinum 247
Bioavailability 232
Bleomycin 168
- oil suspension 274
Bone marrow atuotransplantation 216
Bone marrow rescue 120
Breast cancer 112, 272

Calmodulin 146, 202
CB 3717 265
CCNU 125, 150
Chemosensitivity 104
Chemotherapy 120, 279
Cis-Platinum 222, 250, 258
Cis-Platinum(II) 262
Cisplatin 38
Cisplatin-chemotherapy 235
Clonogenic assay 104
Colorectal cancer 1
Cross-resistance 194
Cyclophosphamide 120, 135, 222
- toxicity 59

Diazepam 250
DMDR 81
Doxorubicin 132
Drug resistance 132
Drug stability in vitro 83

Etoposide 172, 258

Fischer 344 rat 150
5-Fluorouracil 63, 108
Futraful versus 5-FU 282

Gluthatione 188

Hamsters 132
Harringtonine 206
Hexamethylamine 222
High dose corticosteroids 235
HPLC and TLC of doxorubicin 139
HTSCA and CFU-C assay 156
Human leukemia 206
7-Hydroxymethotrexate 165

Immunoassay 53
In vitro cell lines 194
In vitro cytotoxicity 160
In vivo distribution 253
Infusion 26
Interferon 34, 184
L-Alanosine 74
Leukemia 26, 211
Leukemic cells 202
Lomustine 125
Lung adenocarcinoma 282
Lymphoma 206

Marcellomycin 42
Medroxyprogesterone 112
- acetate 229, 232
Mellitin 202
Melphalan 216
Metabolism of bisantrene 15
Metastatic renal cancer 277
Methotrexate absorption 211, 238
Metoclopramide 250
Mitoxantrone 79
Multiple myeloma 34, 49, 279

Nitrosoureas 146, 156
Non-Hodgkin's lymphoma 9, 216

Oral vinzolidine 12

Pancreatic cancer 132
Pharmacodynamics 177
Pharmacokinetics 108, 125, 265
Polysorbate 80 238
Predictive test 116
Prochlorperazine 250
Protein A 59, 135
Pt complexes 253

Rats 135
Renal cell carcinoma 184

Small cell lung carcinoma 9, 120

Tamoxifen 229, 272
Testicular carcinoma 168
Time dependency 104
Tumor cell resistance 96
- metastasis 30
- models 132

Uptake and elimination 238

Verapamil 30
Vincristine 26
VP-16 258